Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
September 17 2013 - 10:06AM
Marketwired
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr.
David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
Senior Vice President of Research and Development at Tacere
Therapeutics (a Subsidiary of Benitec Biopharma) to Help Guide
Regen's Cancer Immunotherapy Program
SAN DIEGO, CA--(Marketwired - Sep 17, 2013) - Bio-Matrix
Scientific Group Inc. (OTCQB: BMSN) announced that it has
recruited, Dr. David Suhy, a pioneer in the field of RNA
Interference (RNAi), to join the Scientific Advisory Board of Regen
BioPharma Inc. ("Regen"), a subsidiary of Bio-Matrix Scientific
Group Inc.
"Dr. Suhy, a pioneer of the RNAi industry, was already
developing therapeutic candidates in this field in 2003 before the
concept of RNAi was accepted in the scientific community," said
David Koos, Chairman & CEO of Regen. "We are excited to apply
Dr. Suhy's experience in the development of our RNAi based cancer
therapeutic."
Regen's Chief Scientific Officer, Dr. Thomas Ichim, noted, "Dr.
David Suhy, senior vice president of research and development at
Tacere Therapeutics (a subsidiary of Benitec Biopharma), leads all
Tacere's clinical development programs. He was one of the inventors
of TT-034, a novel therapeutic product containing three separate
RNAi elements targeted against the Hepatitis C virus, and has
directed development of the TT-03x series of compounds which target
the Hepatitis C virus (HCV), from the drawing board through to
Investigational New Drug (IND) enabling studies."
A spokesperson for the Company provided further insight on RNAi,
stating this is a process by which genes may be selectively blocked
using a natural mechanism the body normally uses to protect against
viruses. The Nobel Prize in Medicine was awarded to Fire and
Mello in 2006 for making this discovery. Benitec has been
granted international patents on RNAi which have been licensed to
Regen for one specific gene, indolamine 2,3 deoxygenase (IDO),
which is associated with cancer's ability to suppress the immune
system.
Regen Chief Scientific Officer Dr. Thomas Ichim together with
Professor Weiping Min at the University of Western Ontario have
successfully treated breast cancer (1) and melanoma (2) in animals
using this approach.
"With Regen's background in the field of tumor immunology, their
licensed intellectual property from Benitec Biopharma, and clinical
expertise, I look forward to assisting the Company in developing
their protocols with the end goal being taking this safe and
nontoxic cancer therapy to patients," said Dr. Suhy.
References
1. Zheng et al. Silencing IDO in dendritic cells: a novel
approach to enhance cancer immunotherapy in a murine breast cancer
model. Int J Cancer. 2013 Feb 15;132(4):967-77.
2. Zheng et al. Reinstalling antitumor immunity by inhibiting
tumor-derived immunosuppressive molecule IDO through RNA
interference. J Immunol. 2006 Oct 15;177(8):5639-46.
3.
http://www.fiercepharma.com/special-reports/yervoy/top-20-orphan-drugs-2018
About Regen BioPharma: Regen BioPharma, Inc., a
subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a
biotechnology company focused on identifying undervalued
regenerative medicine applications in the stem cell space and
rapidly advancing these technologies through pre-clinical and Phase
I/ II clinical trials. For more information refer to the company's
website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking
statements. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or
quantified. Future events and actual results could differ
materially from those set forth in, contemplated by, or underlying
the forward-looking statements. The risks and uncertainties to
which forward looking statements are subject include, but are not
limited to, the effect of government regulation, competition and
other material risks.
Contact: Bio-Matrix Scientific Group, Inc. and Regen BioPharma
Inc. David R. Koos, PhD Chairman & Chief Executive Officer
619-702-1404 www.regenbiopharma.com